The U.S. Food and Drug Administration rejected Eli Lilly’s Biologics License Application, issuing a Complete Response Letter for the company’s PD-1 checkpoint inhibitor sintilimab.

Companies presented very promising data for treating lung cancer at European Society of Medical Oncology (ESMO) Congress 2021.


BeiGene Ltd. will partner with Swiss firm Novartis AG to develop, manufacture and commercialize the China-based biotechnology company’s cancer drug tislelizumab.

Thermo Fisher Scientific and Daiichi Sankyo have partnered to co-develop a companion diagnostic device for patients who have non-small cell lung cancer (NSCLC). 

A preliminary analysis of late-stage trial data showed that BeiGene’s investigational checkpoint inhibitor tislelizumab is hitting the mark as a potential first-line treatment in patients with non-squamous non-small cell lung cancer (NSCLC).